Conditionally replicating adenoviruses as anticancer agents and ways to improve their efficacy.
Conditionally replicating adenoviruses as anticancer agents and ways to improve their efficacy.
复制标题
DOI：
--
复制
发表时间：
2004-04
影响因子：
--
通讯作者：
D. Oosterhoff;V. V. van Beusechem-V.
中科院分区：
文献类型：
--
作者：
D. Oosterhoff;V. V. van Beusechem-V.
条件复制腺病毒（CRAds）作为一种新的癌症治疗工具而发展起来。crad特异性地在癌细胞中复制并杀死癌细胞。在实体肿瘤中，被感染的癌细胞释放出新形成的感染性颗粒，使额外的细胞层被感染和破坏。当作为单一治疗药物使用时，crad在临床试验中仅显示出有限的效果。然而，由CRAd病毒治疗与化疗、放射或酶前药物治疗组成的联合研究显示出附加甚至协同效应，在临床研究中取得了令人鼓舞的结果。此外，在临床前模型中，通过特异性靶向肿瘤细胞的CRAd感染或通过在CRAd基因组中插入治疗基因，可以提高CRAd的疗效。本文综述了实现CRAd特异性的不同机制，CRAd在临床试验中的疗效以及增强其溶瘤效能的方法。
Conditionally replicating adenoviruses (CRAds) were developed as new tools for cancer therapy. CRAds specifically replicate in and kill cancer cells. Within a solid tumor mass, release of newly formed infectious particles from infected cancer cells allows additional cell layers to be infected and destroyed. When used as monotherapeutic agents, CRAds showed only limited effects in clinical trials. Combination studies consisting of CRAd virotherapy with chemo-, radio-or enzyme prodrug therapy, however, showed additive or even synergistic effects and encouraging results in clinical studies. Furthermore, increased CRAd efficacy could be achieved in preclinical models by targeting CRAd infection specifically to tumor cells or via insertion of therapeutic genes in the CRAd genome. In this review, different mechanisms to achieve CRAd specificity, the efficacy of CRAds in clinical trials and ways to enhance their oncolytic potency are discussed.